1. Yamada T, Nakajima A, Inoue E, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Annals of the Rheumatic Diseases, 2006. 65(12): 1661–1663.doi:10.1136/ard.2005.047274
2. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis & Rheumatism, 2009. 61(3): 300–304. doi:10.1002/art.24476
3. Koshy S. Prevalence of pulmonary tuberculosis in rheumatoid arthritis. Int J Res Med Sci. 2016;4(9):3729–32.
4. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm. 2017;2017.
5. Arkema E V., Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis. 2015;74(6):1212–7.
6. Scrivo R, Armignacco O. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: A critical appraisal of national registry data. Int J Rheum Dis. 2014;17(7):714–22.
7. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol, 2010. 161(1): 1-9.
8. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis, 2010. 69 : 522-528.
9. Settas LD, Tsimirikas G, Vosvotekas G, et al. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol, 2007. 13(4): 219-20.
10. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Research and Therapy, 2011. https://doi.org/10.1186/ar3455
11. Diel R, Hauer B, Loddenkemper R, Manger B, Krüger K. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Zeitschrift Für Rheumatologie, 2009. 68(5): 411–416.doi:10.1007/s00393-009-0475-x
12. Kwakernaak AJ, Houtman PM, Weel JFL, Spoorenberg JPL, Jansen TLTA. A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor. Clin Rheumatol. 2011;30(4):505–10.
13. Ramos JM, Robledano C, Masiá M, Belda S, Padilla S, Rodríguez JC, et al. Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis. 2012;169(12)
14. Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Annals of the Rheumatic Diseases, 2012. 71(11): 1791–1795. doi:10.1136/annrheumdis-2011-200941
15. Murakami S, Takeno M, Kirino Y, et al. Screening of tuberculosis by interferon-γ assay before biologic therapy for rheumatoid arthritis. Tuberculosis, 2009. 89(2): 136–141.doi:10.1016/j.tube.2008.12.004
16. Costantino F, de Carvalho Bittencourt M, Rat AC, et al. Screening for Latent Tuberculosis Infection in Patients with Chronic Inflammatory Arthritis: Discrepancies Between Tuberculin Skin Test and Interferon- Release Assay Results. The Journal of Rheumatology, 2013. 40(12): 1986–1993. doi:10.3899/jrheum.130303
17. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon release assays and conventional screening tests before tumour necrosis factor blockade in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2009. 69(01): 181–185. doi:10.1136/ard.2008.101857
18. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016.
19. Duncan KO, Winthrop KL. Reply to: Comment on “Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors.” J Am Acad Dermatol [Internet]. 2015;73(3):e125–6.
20. NICE. Tuberculosis Prevention, diagnosis, management and service organisation. TB Clin Guidel Updat. 2016